Browse our anti-HMMR (HMMR) Antibodies

Mouse (Murine) Hyaluronan-Mediated Motility Receptor (RHAMM) (HMMR) interaction partners

1. These data identify an essential role for HMMR in the PLK1 (show PLK1 Antibodies)-dependent regulatory pathway that orients progenitor cell division and supports neural development.

2. RHAMM localises at the mitotic spindle of ovarian granulosa cells via its C-terminus, deletion of which impairs proper spindle orientation and folliculogenesis.

3. RHAMM is not found on the cell-surface of embryonic stem cells, but it is required to maintain pluripotency and its dominant mechanism of action is through the modulation of signal transduction pathways at microtubules

4. Hyaluronon acid activation of RHAMM significantly impacts smooth muscle cell-ECM (show MMRN1 Antibodies) adhesive interactions and contributes to constrictive artery wall remodeling in mice.

5. This study demonistrated that Rhamm expression in adult mouse subventricular zone and rostral migratory stream and in ischemic cortex.

6. Overexpressing RHAMM was located intracellular and activated ERK1/2.

7. Results suggest that the CD44 (show CD44 Antibodies) and RHAMM receptors function on membrane lipid rafts during Cryptococcus neoformans invasion.

8. RHAMM isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis.

9. intracellular RHAMM(Delta163) functions as an adaptor protein to control microtubule polymerization during interphase and mitosis as a result of localizing ERK1/2-MEK1 (show MAP2K1 Antibodies) complexes to their tubulin (show TUBB Antibodies)-associated substrates

10. Gene deletion of Rhamm attenuates the formation of aggressive fibromatosis.

Human Hyaluronan-Mediated Motility Receptor (RHAMM) (HMMR) interaction partners

1. This pilot study shows, for the first time, that RHAMM may contribute to ovarian cancer disease and could potentially be used as a prognostic marker.

2. The ability to enhance cell polarity through the application of this dielectrophoretic (DEP (show ZDHHC21 Antibodies)) electromagnetic field (EMF) force may offer another way to stabilize HMMR and differentially modulate its expression in cancerous and noncancerous cells.

3. we found that RHAMM-specific T cells are present at vaccination sites in AML (show RUNX1 Antibodies) patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.

4. RHAMM, most likely RHAMMv3 (RHAMMB), can serve as a prognostic factor for lung adenocarcinomas and a potential therapeutic target in non-small cell lung carcinoma to inhibit tumor migration

5. Data show that receptor of hyaluronan-mediated motility (RHAMM) mRNA expression in breast cancer biopsies is inversely correlated with tumor grade and overall survival.

6. spindle-associated (show HAUS1 Antibodies) RHAMM as an intrinsic regulator of male germ cell fate and as a gatekeeper preventing initiation of testicular germ cell tumors (TGCT).

7. Overexpression of the hyaluronan receptor HMMR in primary LUAD was associated with an inflammatory molecular signature and poor prognosis. Attenuating HMMR in LUAD cells diminished their ability to initiate lung tumors and distant metastases.

8. The present study suggests that RHAMM is a novel beta-catenin (show CTNNB1 Antibodies) intracellular binding partner, protecting beta-catenin (show CTNNB1 Antibodies) from degradation and supporting the nuclear translocation of this key cellular mediator

9. RHAMM expression identifies an aggressive subpopulation of tumor budding cells and is an independent adverse prognostic factor for colorectal cancer patients.

10. a causative link between altered function of AURKA-HMMR-TPX2-TUBG1 and breast carcinogenesis in BRCA1/2 mutation carriers